Ships within 24 hours on business days · +10% with Bank Pay

SS-31 (Elamipretide)

Shop

SS-31 (Elamipretide) · Research brief

SS-31 Elamipretide Analogs: How the SS Peptides Compare

60 WORDS

Short answer

SS-31 elamipretide analogs are a small family of water soluble, aromatic cationic tetrapeptides that concentrate in the inner mitochondrial membrane and associate with cardiolipin, the signature phospholipid of that membrane. The group includes the early SS series sequences SS-01, SS-02 and SS-20, the most studied member SS-31 (the compound that received the nonproprietary name elamipretide and carries the development code…

SS-31 elamipretide analogs are a small family of water soluble, aromatic cationic tetrapeptides that concentrate in the inner mitochondrial membrane and associate with cardiolipin, the signature phospholipid of that membrane. The group includes the early SS series sequences SS-01, SS-02 and SS-20, the most studied member SS-31 (the compound that received the nonproprietary name elamipretide and carries the development code MTP-131), and later compounds built on the same alternating aromatic and basic motif. The analogs differ in which aromatic residue occupies which position, whether a 2',6'-dimethyltyrosine residue is present, and how strongly each one partitions into lipid bilayers. Those structural differences are what comparative research tries to connect to function. This brief sets the structures side by side, reviews what named and citable studies report, and marks clearly where the published record stops.

What compounds belong to the SS peptide family and how do they differ structurally?

The SS series is a set of tetrapeptide amides in which aromatic residues alternate with basic residues, giving each molecule a net positive charge of 3 at physiological pH together with unusual water solubility for a membrane active compound. The original series description, Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury (Journal of Biological Chemistry, 2004), introduced several of these sequences and reported that they localise to the inner mitochondrial membrane in isolated mitochondria and in cells. The practical consequence for a comparison page is that the family is defined by a motif rather than by a single pharmacophore: swap the aromatic residue at position one, move the dimethyltyrosine, or remove the phenol entirely, and the resulting peptide still reaches the same compartment but is reported to behave differently once it arrives.

Compound Sequence or structure Distinguishing feature How the literature positions it
SS-01 Tyr-D-Arg-Phe-Lys-NH2 Plain tyrosine at position 1 Early series member used to establish the aromatic cationic motif
SS-02 Dmt-D-Arg-Phe-Lys-NH2 2',6'-dimethyltyrosine at position 1 Series member with the dimethylated phenol at the N-terminus
SS-20 Phe-D-Arg-Phe-Lys-NH2 No tyrosine or Dmt, so no phenolic hydroxyl Used as a comparator peptide that retains the motif without the phenol
SS-31 (elamipretide, MTP-131) D-Arg-Dmt-Lys-Phe-NH2 D-arginine first, Dmt internal The most extensively studied member and the subject of most mechanistic work
SBT-272 Structure not specified in the sources verified for this brief Described publicly as a successor compound from the same chemistry Positioned as a later mitochondria-targeted molecule; see the dedicated section below
MitoQ Ubiquinone joined to a triphenylphosphonium cation Not a peptide; lipophilic cation targeting Comparator class rather than an analog
SkQ1 Plastoquinone joined to a triphenylphosphonium cation Not a peptide; lipophilic cation targeting Comparator class rather than an analog

The table is deliberately conservative. Where a structure has not been published in a source that can be checked, this page says so rather than filling the cell with a plausible guess. Researchers evaluating any of these compounds for laboratory work should confirm sequence, molecular formula and CAS identity against the certificate of analysis for the specific lot rather than relying on a summary table.

How does SS-31 reach the inner mitochondrial membrane without a lipophilic cation?

It partitions there by virtue of its own charge and aromatic surface rather than by being dragged across the membrane by the electrical gradient. This is the clearest point of separation between the SS peptides and the triphenylphosphonium class. A lipophilic cation such as the one used in MitoQ accumulates in the matrix in proportion to membrane potential, which means uptake falls as mitochondria depolarise and rises when they are healthy. The SS series is described in the 2004 Journal of Biological Chemistry report as concentrating in the inner mitochondrial membrane in a manner that does not depend on the potential in the same way, which in principle allows a damaged organelle to still be reached.

The physical basis for that behaviour has been examined directly. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action (Journal of Biological Chemistry, 2020) reports binding to lipid bilayers and a change in the electrostatic character of the membrane surface, and argues that this surface effect is central rather than incidental. That framing matters for anyone comparing analogs, because it suggests the relevant variable is how a given sequence inserts into and organises an anionic bilayer, not simply whether it carries a reactive phenol. The limits are the usual ones for biophysical work: model bilayers are not mitochondria, and the step from an electrostatics measurement in vitro to an outcome in a living cell is an inference rather than a demonstration.

What does the interaction with cardiolipin actually change?

Cardiolipin is the four tailed, doubly anionic phospholipid that is largely confined to the inner mitochondrial membrane, where it shapes cristae curvature, holds respiratory complexes together and binds cytochrome c. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin (Journal of the American Society of Nephrology, 2013) describes an interaction with cardiolipin and reports recovery of energetic function in ischemic mitochondria, which is the finding that reoriented the field away from a purely antioxidant reading of these peptides.

The proposed mechanism runs through cytochrome c. When cytochrome c associates tightly with cardiolipin it can take on peroxidase character, which both diverts it from electron transfer and generates lipid peroxidation products. Research suggests that a peptide bound at the cardiolipin surface can modify that association so that cytochrome c behaves more as an electron carrier and less as a peroxidase. If that reading is correct, then an analog's value is set by its affinity for cardiolipin-rich membrane and by the geometry it imposes once bound, which gives a concrete hypothesis for why small sequence changes across the SS series would matter. The caveats are that most of this work is in isolated mitochondria or acute injury models, and that cardiolipin biology differs between tissues, so results in kidney or heart preparations do not automatically generalise.

How do SS-01, SS-02 and SS-20 compare with SS-31 in published work?

The early series members matter mainly as structural controls that let investigators separate one property from another. SS-01 and SS-02 carry a phenolic residue at the N-terminus, with SS-02 bearing the dimethylated version; SS-20 carries no phenol at all; SS-31 moves the dimethyltyrosine inward and puts D-arginine first. Because SS-20 retains the aromatic cationic motif but not the phenolic hydroxyl, the literature describes it as a useful comparator for asking whether an observed effect requires radical scavenging chemistry or only membrane association. The 2004 Journal of Biological Chemistry series paper is the primary citable source for the family as a set.

What the published record does not provide, at least in the sources verified for this brief, is a clean head to head ranking of all four peptides across a standard panel of assays in the same laboratory under the same conditions. Comparisons are scattered across models, cell types and readouts, which is exactly the situation in which apparent differences can reflect experimental context rather than chemistry. A researcher building a comparison should therefore treat the SS series as a scaffold with several documented variants, run the variants in parallel internally if a ranking is needed, and avoid importing potency statements from one model into another. Where a specific comparative figure is quoted elsewhere without a traceable citation, it should be treated as unverified.

Is SS-31 better described as an antioxidant or as a membrane-active peptide?

Both descriptions appear in the literature, and the shift from the first to the second is the single most important change in how this compound class is understood. The 2004 series paper framed these peptides as cell permeable antioxidants targeted to the inner membrane, with the dimethyltyrosine supplying scavenging capacity. The 2013 cardiolipin paper and the 2020 bilayer electrostatics paper reframe the compound as a membrane-interacting agent whose primary action is on the organisation of an anionic lipid surface and the proteins that sit on it.

These readings are not mutually exclusive. A molecule that concentrates at the inner membrane is well placed to intercept lipid radicals there, and a molecule that keeps cytochrome c in its electron-transfer role would reduce radical production upstream. For comparative purposes the distinction still matters, because the two models predict different things about analogs. A scavenging model predicts that removing the phenol should abolish activity. A membrane-organising model predicts that a phenol-free analog retaining the charge and aromatic pattern could still be active. The published series work gives reason to take the second possibility seriously, but the literature verified here does not settle the question, and any statement that one mechanism has been proven dominant goes beyond what the citable sources support.

What do aging and muscle models report for SS-31?

Two reports in aged mice are the commonly cited entry points. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice (Aging Cell, 2013) reports improvement in mitochondrial energetics and in skeletal muscle performance in aged animals, and the word rapidly in its title reflects the short interval between exposure and measurable change, which is itself an argument for a direct effect on existing organelles rather than for slow remodelling of mitochondrial content. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice (Free Radical Biology and Medicine, 2019) reports improvement in age-related redox stress together with better exercise tolerance in aged mice.

These are animal studies with the limits that implies. Aged mouse muscle is a convenient system because the energetic deficit is reproducible and measurable, but it is not a model of any specific human condition, and short-interval functional gains in rodents have a poor record of transferring intact to clinical settings. Neither paper establishes what happens over long exposure windows, in other tissues, or in genetically defined mitochondrial disease. They are best read as evidence that an acutely acting, membrane-associated peptide can change bioenergetic readouts in an intact animal, which is a meaningful mechanistic claim and a modest translational one.

What is SBT-272 and how is it positioned relative to elamipretide?

SBT-272 is publicly described as a later mitochondria-targeted compound developed from the same chemistry programme that produced elamipretide, with the stated design goal of better distribution into the central nervous system. Beyond that positioning, this page does not restate specific preclinical findings for SBT-272, because the corresponding publications are not among the sources verified for this brief, and the house rule here is that a specific study claim carries its citation or is not made. Researchers who need the primary data should search the compound code directly on PubMed and read the original reports rather than relying on secondary summaries.

What can be said structurally is also limited. The detailed structure of SBT-272 is not specified in the sources verified for this brief, so it cannot be placed in the sequence table alongside the SS tetrapeptides with any confidence. That is an honest gap rather than an oversight: compounds in active commercial development are often described in conference material and press releases long before a full structural and pharmacological account appears in a peer reviewed journal, and a supplier-side research brief is not the place to reconstruct one. Anyone comparing elamipretide with a successor compound should note that the available evidence base is highly asymmetric, with one molecule carrying two decades of mechanistic literature and the other far less.

How do mitochondria-targeted peptides compare with TPP-conjugated small molecules such as MitoQ and SkQ1?

They solve the same targeting problem by different physical means, and that difference drives most of the practical contrasts. MitoQ joins a ubiquinone to a triphenylphosphonium cation, and SkQ1 joins a plastoquinone to the same kind of cation. The lipophilic cation drives accumulation in the matrix in response to the membrane potential, so uptake is steep in well polarised mitochondria and falls as the potential collapses. The redox-active head group then participates in electron chemistry, which is why this class is conventionally discussed as a targeted antioxidant strategy with a redox cycling component.

The SS peptides are not lipophilic cations and do not carry a quinone. They are polar, water soluble molecules that associate with an anionic lipid surface, and the mechanistic literature discussed above frames their action in terms of membrane organisation and cytochrome c behaviour rather than redox cycling. Two comparative implications follow. First, in a model where mitochondria are depolarised, the two classes should not be expected to reach the organelle equally well. Second, dependence on redox chemistry differs, so assays built around a radical probe may register the two classes very differently even when both improve a functional readout. This page does not cite specific MitoQ or SkQ1 studies; the description here is of compound class and targeting principle only.

Where do mitochondria-derived peptides such as Humanin and MOTS-c fit in this comparison?

They belong to a separate category and are frequently confused with the SS series because both are peptides associated with mitochondria. Humanin and MOTS-c are encoded within the mitochondrial genome and are described in the literature as signalling molecules, meaning the working hypothesis is that they act through receptors and intracellular pathways in a manner closer to a hormone than to a membrane-active chemical. The SS peptides are synthetic, are not encoded anywhere, and the mechanistic work on them concerns direct physical association with a lipid membrane.

The practical point for a comparison page is that these classes are not substitutes for one another in experimental design. A laboratory asking whether cristae organisation and electron transfer can be stabilised directly is working on the SS series question. A laboratory asking whether a mitochondrial stress signal can be mimicked is working on the mitochondria-derived peptide question. Readouts overlap, which is part of why the categories get blurred in summaries, but the hypotheses do not. This section makes no claim about the relative effect sizes of the two classes, because no source verified for this brief compares them directly.

What does the clinical research programme on elamipretide tell a laboratory, and what are its limits?

Elamipretide has been studied in company-sponsored clinical research in rare mitochondrial disease and in ophthalmology. This page does not restate outcomes, endpoint results or regulatory determinations from that programme, because the corresponding publications and agency documents are not among the sources verified for this brief, and reporting such specifics without a traceable citation is exactly the failure mode this format is designed to avoid. Researchers who need the trial record should consult the primary publications and the relevant registry entries directly.

What a laboratory can take from the existence of that programme is narrower and still useful. A compound that has been through structured human research has, by necessity, an unusually detailed preclinical and analytical file behind it, including synthesis, identity and stability work that sets a reference standard for what a well characterised lot of this peptide looks like. It also means that the research-use material and the clinical material share a molecular identity, which is why verification of identity against a lot certificate matters more here, not less. None of this makes the compound a human therapeutic in any other setting. Regulatory status varies by jurisdiction and by indication and is outside the scope of this brief.

What assays and readouts are used when these analogs are compared?

Comparative work in this field tends to use a recognisable panel, and knowing the panel makes published claims easier to weigh. Respirometry is the backbone, reporting oxygen consumption under basal, uncoupled and inhibited conditions so that coupling efficiency and spare capacity can be separated. Membrane potential is read with cationic fluorescent indicators, with the standing caveat that probes which themselves accumulate by potential can interact awkwardly with compounds that alter surface charge. ATP production, often measured by luminescence, is reported alongside respiration because the two can diverge.

Structural readouts carry a lot of weight in this literature because the proposed mechanism is physical. Electron microscopy of cristae architecture, blue native electrophoresis for respiratory supercomplex assembly, and lipid analysis for cardiolipin content and oxidation state all speak to the membrane hypothesis more directly than a radical probe does. Biophysical work with model bilayers, as in the 2020 Journal of Biological Chemistry report, supplies the binding and surface electrostatics measurements. In animal work, phosphorus magnetic resonance spectroscopy and fatigue protocols provide functional endpoints, as the aged mouse studies illustrate. For analog comparison specifically, the methodological requirement is that all compounds run in the same system with the same exposure concentrations, which is not the case across most of the published literature as it currently stands.

What are the main limitations and open questions in the analog literature?

The largest gap is the absence of a systematic, single-laboratory comparison of the SS variants and their successors across a standard assay panel. Without that, statements ranking one analog above another rest on cross-study inference. A second gap concerns tissue specificity: cardiolipin abundance, fatty acid composition and remodelling enzymes differ between heart, kidney, muscle, brain and retina, so a membrane-targeting compound might reasonably behave differently in each, and the literature does not currently resolve this.

A third open question is the relationship between acute biophysical effects and durable biological change. Several reports describe rapid shifts in bioenergetic readouts, which argues for direct action on existing organelles, yet much of the interest in this class concerns slower processes such as cristae remodelling and protein quality control. Whether the fast and slow observations share one mechanism is not established by the sources cited here. Finally, almost all of the mechanistic work focuses on a single family member. Elamipretide has the deepest file by a wide margin, and that imbalance means the family is often described through the properties of one molecule. Research suggests the scaffold is more versatile than that, but the evidence for the other members remains thin.

How should concentration be thought about for laboratory work with these peptides?

Real Peptides does not provide preparation or use guidance for any catalog compound, because everything supplied is for laboratory research use only. What can be described is the measurement framework the literature uses. Peptide quantities are expressed in milligrams, solution strength in milligrams per millilitre, and cell or organelle experiments in molar terms, which is why the molecular weight listed on a certificate of analysis is the piece of information that links a vial label to a planned experiment.

Two properties of this compound class are worth noting at the planning stage. These peptides are unusually water soluble for membrane-active molecules, which simplifies handling relative to lipophilic comparators such as the triphenylphosphonium conjugates, and they are short sequences with a C-terminal amide, so the stability considerations are those of small synthetic peptides generally rather than of large biologics. Specific stability, storage and solubility figures vary by lot and by solvent system and are not specified in the sources verified for this brief, so they should be taken from the documentation accompanying the material and from the laboratory's own validation.

How can a laboratory verify identity and quality before procurement?

Verification starts with identity, not with claims. For this compound class that means matching the stated sequence, the molecular formula and the CAS number on the supplier documentation against the chemical identity recorded in the literature for the specific analog in question, since SS-31, elamipretide and MTP-131 all refer to the same molecule and a catalog may use any of those labels. Mass spectrometry and chromatographic identity data on a lot certificate are the documents that make a label checkable rather than assertable.

Real Peptides supplies research-use-only compounds and publishes independent third-party certificates of analysis for every batch at /coas/. The SS-31 catalog listing is at SS-31 (elamipretide), with background material on the compound at /ss-31/, the full catalog at /shop/ and company location information at /location/. A laboratory comparing sources can read a published certificate before procurement, confirm that the lot number on the document matches the material offered, and confirm that the analytical methods reported are the ones appropriate to a short synthetic peptide. Those checks are the same regardless of which member of this family is being purchased, and they are what separates a documented research chemical from an undocumented one.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004. PMID: 15178689. pubmed.ncbi.nlm.nih.gov/15178689
  • The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215. pubmed.ncbi.nlm.nih.gov/23813215
  • Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013. PMID: 23692570. pubmed.ncbi.nlm.nih.gov/23692570
  • Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine. 2019. PMID: 30597195. pubmed.ncbi.nlm.nih.gov/30597195
  • The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020. PMID: 32273339. pubmed.ncbi.nlm.nih.gov/32273339

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Yes. SS-31 is the research designation for the aromatic cationic tetrapeptide D-Arg-Dmt-Lys-Phe-NH2, elamipretide is the nonproprietary name used in clinical development, and MTP-131 is a development code for the same molecule. Catalog listings may use any of these labels, so identity should be confirmed against lot documentation.
SS-20, with the sequence Phe-D-Arg-Phe-Lys-NH2, carries neither tyrosine nor dimethyltyrosine and therefore has no phenolic hydroxyl. The series literature describes it as retaining the aromatic cationic motif, which makes it a useful comparator when separating membrane association from scavenging chemistry in experimental design.
It is publicly positioned as a later mitochondria-targeted compound from the same chemistry programme, with central nervous system distribution as a stated design goal. Its detailed structure is not specified in the sources verified for this brief, so this page makes no structural or comparative performance claim about it.
MitoQ and SkQ1 are quinones joined to a triphenylphosphonium cation, so they accumulate in proportion to mitochondrial membrane potential and act through redox chemistry. The SS peptides are water soluble, carry no quinone, and the mechanistic literature frames their action as association with anionic membrane lipid, particularly cardiolipin.
No. Real Peptides does not provide preparation or use guidance, because everything supplied is for laboratory research use only. The published measurement framework is milligrams per millilitre for solution strength and micrograms per assay at the bench, with protocol design remaining the responsibility of the investigating laboratory.
Respirometry, ATP output, membrane potential indicators, cristae ultrastructure by electron microscopy, respiratory supercomplex analysis, cardiolipin lipid analysis and biophysical binding measurements in model bilayers. Animal work adds phosphorus magnetic resonance spectroscopy and fatigue protocols. Meaningful ranking requires all compounds run in one system under matched conditions.
Not in the sources verified for this brief. Most mechanistic work concerns a single family member, and comparisons across the series are scattered over different models, cell types and readouts. Research suggests the scaffold tolerates variation, but a systematic single-laboratory ranking of the analogs has not been established here.
Match the stated sequence, molecular formula and CAS identity against the chemical record for that specific analog, then read the lot certificate of analysis for mass spectrometry and chromatographic identity data. Real Peptides publishes independent third-party certificates for every batch at /coas/, each tied to a lot number.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now